Clinical Trial Update: Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor [Phase 3]

View source ↗

Summary

Phase 3 trial update indicates OSE2101, a therapeutic cancer vaccine, is being studied in non-small cell lung cancer patients with secondary resistance to immun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• OSE2101

Snippet

Sponsor: OSE Immunotherapeutics | Conditions: Patients With Non-Small Cell Lung Cancer | Phase 3 | Status: RECRUITING